NCT02416453 is a Phase 2 clinical trial of MVA-BN-Filo in Ebola Viral Disease, sponsored by Janssen Vaccines & Prevention B.V..

Who is sponsoring NCT02416453?

NCT02416453 is sponsored by Janssen Vaccines & Prevention B.V..

What drugs are being tested in NCT02416453?

Interventions in NCT02416453: MVA-BN-Filo, Ad26.ZEBOV, Placebo.

What condition does NCT02416453 study?

NCT02416453 studies Ebola Viral Disease.

Is NCT02416453 still recruiting?

NCT02416453 is currently completed. Last updated 8 February 2021.

Are results published for NCT02416453?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-02-08 · How we verify

NCT02416453

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Completed Phase 2 Results posted Last updated 8 February 2021

What this trial tests

Phase 2 trial testing MVA-BN-Filo in Ebola Viral Disease in 423 participants. Completed in 19 January 2018.

Timeline

15 June 2015

Primary endpoint
19 January 2018

19 January 2018

Quick facts

Lead sponsor	Janssen Vaccines & Prevention B.V.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	423
Start date	15 June 2015
Primary completion	19 January 2018
Estimated completion	19 January 2018
Sites	11 locations across France, United Kingdom

Drugs / interventions tested

MVA-BN-Filo — full drug profile →
Ad26.ZEBOV — full drug profile →
Placebo

Conditions studied

Ebola Viral Disease — all drugs for Ebola Viral Disease →

Sponsor

Janssen Vaccines & Prevention B.V. — full company profile →

Who can join

Adults 18 to 65, any sex, with Ebola Viral Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Unsolicited Adverse Events (Groups 1, 2 and 3) Primary · Up to 42-day post dose 2 visit (Day 1 to Day 127)

An adverse event (AE) is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	4
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	6
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	6
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	62
Group 1: Pooled Cohorts II and III: Placebo	6
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	52
Group 2: Pooled Cohorts II and III: Placebo	7
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	46
Group 3: Pooled Cohorts II and III: Placebo	8

Number of Participants With Serious Adverse Events (Groups 1, 2 and 3) Primary · Up to Day 365

A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	0
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	1
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	0
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	2
Group 1: Pooled Cohorts II and III: Placebo	0
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	4
Group 2: Pooled Cohorts II and III: Placebo	1
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	5
Group 3: Pooled Cohorts II and III: Placebo	1

Number of Participants With Immediate Reportable Events (Groups 1, 2 and 3) Primary · Up to Day 365

The following neuroinflammatory disorders were considered immediate reportable events and which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myelor

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	0
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	0
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	0
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	0
Group 1: Pooled Cohorts II and III: Placebo	0
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	2
Group 2: Pooled Cohorts II and III: Placebo	0
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	2
Group 3: Pooled Cohorts II and III: Placebo	0

Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3) Primary · 7 days post-dose 1 (Day 8)

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Solicited local AEs were pre-defined local (at the injection site) AEs for which participants were specifically questioned and which were noted by participants in their diary for 7 days post first vaccination. Solicited local AEs were: injection site pain/tenderness, erythema, induration/swelling, itching at the vaccination site.

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	8
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	6
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	8
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	63
Group 1: Pooled Cohorts II and III: Placebo	3
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	65
Group 2: Pooled Cohorts II and III: Placebo	2
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	78
Group 3: Pooled Cohorts II and III: Placebo	4

Number of Participants With Solicited Local Adverse Events (Groups 1, 2 and 3) Primary · 7 days post-dose 2 (Up to Day 92)

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	4
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	5
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	8
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	46
Group 1: Pooled Cohorts II and III: Placebo	2
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	49
Group 2: Pooled Cohorts II and III: Placebo	0
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	41
Group 3: Pooled Cohorts II and III: Placebo	0

Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3) Primary · 7 days post-dose 1 (Day 8)

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. Participants were instructed on how to note signs and symptoms in the diary on a daily basis for 7 days post-vaccination (Day of vaccination and the subsequent 7 days) for solicited systemic AEs. Solicited systemic events included fever, headache, fatigue/malaise, myalgia, nausea/vomiting, arthralgia and chills.

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	8
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	10
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	10
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	89
Group 1: Pooled Cohorts II and III: Placebo	7
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	84
Group 2: Pooled Cohorts II and III: Placebo	8
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	82
Group 3: Pooled Cohorts II and III: Placebo	7

Number of Participants With Solicited Systemic Adverse Events (Groups 1, 2 and 3) Primary · 7 days post-dose 2 (Up to Day 92)

Group	Value	95% CI
Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	6
Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	5
Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)	5
Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)	42
Group 1: Pooled Cohorts II and III: Placebo	5
Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)	36
Group 2: Pooled Cohorts II and III: Placebo	2
Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)	38
Group 3: Pooled Cohorts II and III: Placebo	4

Number of Participants With Unsolicited Adverse Events (Group 4) Secondary · Up to 28-day post dose 1 (Day 29)

An AE is any untoward medical occurrence in a clinical study subject administered a medicinal product, it does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal product. Unsolicited adverse events were events which were reported by the participant voluntarily or obtained by means of interviewing the participant in a nondirected mann

Group	Value	95% CI
Group 4: Ad26.ZEBOV	6
Group 4: Placebo	1

Number of Participants With Serious Adverse Events (Group 4) Secondary · Up to Day 180

A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Group	Value	95% CI
Group 4: Ad26.ZEBOV	2
Group 4: Placebo	0

Number of Participants With Immediate Reportable Events (Group 4) Secondary · Up to Day 180

The following neuroinflammatory disorders were considered immediate reportable events which had to be reported to the sponsor within 24 hours of becoming aware of the event. Neuroinflammatory disorders included: cranial nerve disorders including paralyses/paresis (example: bell's palsy), optic neuritis, multiple sclerosis, transverse myelitis, guillain-barre syndrome including miller fisher syndrome, bickerstaff's encephalitis and other variants, acute disseminated encephalomyelitis, including site-specific variants (example: non-infectious encephalitis, encephalomyelitis, myelitis, myeloradic

Group	Value	95% CI
Group 4: Ad26.ZEBOV	0
Group 4: Placebo	0

Number of Participants With Solicited Local Adverse Events (Group 4) Secondary · 7 days after each vaccination (Up to Day 8)

Group	Value	95% CI
Group 4: Ad26.ZEBOV	8
Group 4: Placebo	0

Number of Participants With Solicited Systemic Adverse Events (Group 4) Secondary · 7 days after each vaccination (Up to Day 8)

Group	Value	95% CI
Group 4: Ad26.ZEBOV	11
Group 4: Placebo	1

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to Day 365. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Group 1: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)

Serious: 0/10 (0%)

Deaths: 0/10

Group 2: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)

Serious: 1/10 (10%)

Deaths: 0/10

Group 3: Cohort I: Ad26.ZEBOV, MVA-BN-Filo (84-Day Interval)

Serious: 0/10 (0%)

Deaths: 0/10

Group 1: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (28-Day Interval)

Serious: 2/112 (2%)

Deaths: 0/112

Group 1: Pooled Cohorts II and III: Placebo

Serious: 0/13 (0%)

Deaths: 0/13

Group 2: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo (56-Day Interval)

Serious: 4/114 (4%)

Deaths: 0/114

Group 2: Pooled Cohorts II and III: Placebo

Serious: 1/13 (8%)

Deaths: 0/13

Group 3: Pooled Cohorts II and III: Ad26.ZEBOV, MVA-BN-Filo, (84-Day Interval)

Serious: 5/106 (5%)

Deaths: 0/106

Group 3: Pooled Cohorts II and III: Placebo

Serious: 1/18 (6%)

Deaths: 0/18

Group 4: Ad26.ZEBOV

Serious: 2/13 (15%)

Deaths: 0/13

Group 4: Placebo

Serious: 0/2 (0%)

Deaths: 0/2

Serious adverse events (15 terms)

Reaction	System	Group 1: Cohort I: Ad26.ZE…	Group 2: Cohort I: Ad26.ZE…	Group 3: Cohort I: Ad26.ZE…	Group 1: Pooled Cohorts II…	Group 1: Pooled Cohorts II…	Group 2: Pooled Cohorts II…	Group 2: Pooled Cohorts II…	Group 3: Pooled Cohorts II…	Group 3: Pooled Cohorts II…	Group 4: Ad26.ZEBOV	Group 4: Placebo
Haemorrhoids	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Inguinal hernia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Cholecystitis acute	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—
Food allergy	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Chronic sinusitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Hepatitis A	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Human papilloma virus test positive	Investigations	—	—	—	—	—	—	—	—	—	—	—
Breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Osteosarcoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—
Cerebral venous thrombosis	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Miller Fisher syndrome	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Small fibre neuropathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Abortion spontaneous	Pregnancy, puerperium and perinatal conditions	—	—	—	—	—	—	—	—	—	—	—
Appendicectomy	Surgical and medical procedures	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (43 terms — click to expand)

Reaction	System	Group 1: Cohort I: Ad26.ZE…	Group 2: Cohort I: Ad26.ZE…	Group 3: Cohort I: Ad26.ZE…	Group 1: Pooled Cohorts II…	Group 1: Pooled Cohorts II…	Group 2: Pooled Cohorts II…	Group 2: Pooled Cohorts II…	Group 3: Pooled Cohorts II…	Group 3: Pooled Cohorts II…	Group 4: Ad26.ZEBOV	Group 4: Placebo
Rhinitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Neutrophil count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Influenza like illness	General disorders	—	—	—	—	—	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—	—	—
Dental discomfort	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Odynophagia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Oral pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—
Application site bruise	General disorders	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Injection site erythema	General disorders	—	—	—	—	—	—	—	—	—	—	—
Injection site pain	General disorders	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Tooth abscess	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—
Ligament sprain	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—	—	—	—	—	—
Prothrombin time prolonged	Investigations	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Chondropathy	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Osteoarthritis	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—
Dizziness postural	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—
Asthma	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Haemorrhoids, Inguinal hernia, Cholecystitis acute, Food allergy, Cellulitis, Chronic sinusitis, Hepatitis A, Human papilloma virus test positive.

Data from ClinicalTrials.gov NCT02416453 adverse events section.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, et al · · 2021 · cited 129× · PMID 33217361 · DOI 10.1016/s1473-3099(20)30476-x
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Custers J, Kim D, Leyssen M, Gurwith M, et al · · 2021 · cited 59× · PMID 33676782 · DOI 10.1016/j.vaccine.2020.09.018
Targeting natural killer cells to enhance vaccine responses.
Cox A, Cevik H, Feldman HA, Canaday LM, et al · · 2021 · cited 47× · PMID 34311992 · DOI 10.1016/j.tips.2021.06.004
Ebola: Lessons on Vaccine Development.
Feldmann H, Feldmann F, Marzi A. · · 2018 · cited 40× · PMID 30200851 · DOI 10.1146/annurev-micro-090817-062414
Ebola vaccines in clinical trial: The promising candidates.
Wang Y, Li J, Hu Y, Liang Q, et al · · 2017 · cited 40× · PMID 27764560 · DOI 10.1080/21645515.2016.1225637
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.
Suschak JJ, Schmaljohn CS. · · 2019 · cited 37× · PMID 31589088 · DOI 10.1080/21645515.2019.1651140
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
Goldstein N, Bockstal V, Bart S, Luhn K, et al · · 2022 · cited 31× · PMID 32939546 · DOI 10.1093/infdis/jiaa586
Ebola Virus Infection: Overview and Update on Prevention and Treatment.
Martínez MJ, Salim AM, Hurtado JC, Kilgore PE. · · 2015 · cited 23× · PMID 26363787 · DOI 10.1007/s40121-015-0079-5

Verify or expand the search:

Other trials of MVA-BN-Filo

Trials testing the same drug.

NCT04556526 — A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women · Phase 3 · completed
NCT04228783 — A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants · Phase 3 · completed
NCT03929757 — A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants · Phase 2 · completed
NCT02876328 — Partnership for Research on Ebola VACcinations · Phase 2 · completed
NCT02661464 — Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo · Phase 3 · terminated

Other Janssen Vaccines & Prevention B.V. trials

Trials by the same sponsor.

NCT05901636 — A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults · Phase 1, PHASE2 · completed
NCT05327816 — A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Year · Phase 1, PHASE2 · terminated
NCT05091307 — A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults · Phase 3 · completed
NCT05101486 — A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years · Phase 3 · completed
NCT05083585 — A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Ag · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02416453 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Vaccines & Prevention B.V.
Last refreshed: 8 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02416453.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02416453

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (15 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of MVA-BN-Filo

Other Janssen Vaccines & Prevention B.V. trials

Verify against primary sources